Lucid Diagnostics (NASDAQ:LUCD) Posts Quarterly Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) released its earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, Yahoo Finance reports. The business had revenue of $1.04 million during the quarter. Lucid Diagnostics had a negative return on equity of 8,334.14% and a negative net margin of 2,169.07%. During the same quarter in the prior year, the firm earned ($0.22) EPS.

Lucid Diagnostics Stock Performance

NASDAQ LUCD opened at $0.99 on Thursday. The firm’s 50 day moving average price is $1.29 and its two-hundred day moving average price is $1.34. Lucid Diagnostics has a twelve month low of $0.97 and a twelve month high of $1.85.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of Lucid Diagnostics during the 4th quarter valued at $29,000. LPL Financial LLC lifted its holdings in shares of Lucid Diagnostics by 97.2% during the 3rd quarter. LPL Financial LLC now owns 28,400 shares of the company’s stock valued at $33,000 after buying an additional 14,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Lucid Diagnostics in the 2nd quarter valued at approximately $87,000. BlackRock Inc. increased its holdings in Lucid Diagnostics by 39.5% in the second quarter. BlackRock Inc. now owns 26,304 shares of the company’s stock worth $37,000 after buying an additional 7,448 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Lucid Diagnostics by 245.3% in the second quarter. Geode Capital Management LLC now owns 143,465 shares of the company’s stock valued at $199,000 after acquiring an additional 101,922 shares during the last quarter. 74.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald cut their price objective on Lucid Diagnostics from $3.80 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $2.50 price target on shares of Lucid Diagnostics in a research report on Wednesday.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.